Search research articles
Contact Us
Filters
Showing results (41-50 of 52) with videos related to
Page
of 6
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
May 5, 2017
First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A
K Hampton, P Chowdary, S Dunkley, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
October 3, 2014
Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials
E Santagostino, S R Lentz, M Misgav, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
August 3, 2018
Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee
P W Collins, R Liesner, M Makris, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
February 22, 2017
Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A
A D Shapiro, J N Mahlangu, D Perry, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
August 3, 2016
Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX
M A Escobar, R Tehranchi, F A Karim, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
January 28, 2015
Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A
R Kruse-Jarres, J St-Louis, A Greist, et al.
Journal of Thrombosis and Haemostasis : JTH
|
August 29, 2018
Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia
R A Gruppo, D Malan, J Kapocsi, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
July 7, 2012
Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis
U Martinowitz, A Shapiro, D V Quon, et al.
Journal of Thrombosis and Haemostasis : JTH
|
February 3, 2015
Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial
P Chowdary, S Lethagen, U Friedrich, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
August 24, 2017
Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients
P W Collins, D V K Quon, M Makris, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 52) with videos related to
Sort By:
Page
of 6
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
May 5, 2017
First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A
K Hampton, P Chowdary, S Dunkley, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
October 3, 2014
Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials
E Santagostino, S R Lentz, M Misgav, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
August 3, 2018
Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee
P W Collins, R Liesner, M Makris, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
February 22, 2017
Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A
A D Shapiro, J N Mahlangu, D Perry, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
August 3, 2016
Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX
M A Escobar, R Tehranchi, F A Karim, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
January 28, 2015
Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A
R Kruse-Jarres, J St-Louis, A Greist, et al.
Journal of Thrombosis and Haemostasis : JTH
|
August 29, 2018
Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia
R A Gruppo, D Malan, J Kapocsi, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
July 7, 2012
Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis
U Martinowitz, A Shapiro, D V Quon, et al.
Journal of Thrombosis and Haemostasis : JTH
|
February 3, 2015
Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial
P Chowdary, S Lethagen, U Friedrich, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
August 24, 2017
Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients
P W Collins, D V K Quon, M Makris, et al.
Page
of 6